Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psoriasis induced by topical imiquimod.

Jason K Wu1, Greg Siller, Geoff Strutton

  • 1Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

The Australasian Journal of Dermatology
|February 14, 2004
PubMed
Summary

Topical imiquimod cream can trigger localized psoriasis flares at application sites in patients with pre-existing psoriasis. This reaction may progress to a generalized psoriatic eruption, even after treatment cessation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Booster Immunisation with Skin-Patch-Delivered Unadjuvanted SARS-CoV-2 Spike Protein Vaccine Is Safe and Immunogenic in Healthy Adults.

Vaccines·2026
Same author

High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia.

Dermatology and therapy·2017
Same author

Teledermatologists' management of emergency skin conditions.

The Medical journal of Australia·2015
Same author

Comedonal Darier's disease diagnosed incidentally in a patient undergoing a routine skin examination for sun cancer.

The Australasian journal of dermatology·2014
Same author

Pigmented spindle cell naevus of Reed: a controversial diagnostic entity in Australia.

The Australasian journal of dermatology·2011
Same author

PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.

The Australasian journal of dermatology·2010

Area of Science:

  • Dermatology
  • Oncology

Background:

  • Psoriasis is a chronic autoimmune disease.
  • Imiquimod is a topical immune response modifier used to treat skin cancers.

Observation:

  • A patient with long-standing stable psoriasis was treated with topical imiquimod for basal cell carcinomas.
  • Psoriasiform changes occurred at all three imiquimod application sites.
  • The patient later developed a disseminated psoriatic eruption.

Findings:

  • Topical imiquimod can induce localized psoriasis at application sites.
  • Psoriasis provocation may occur even after imiquimod treatment completion.
  • The induced psoriasis responded to conventional treatments.

Implications:

Related Experiment Videos

  • Clinicians should be aware of the potential for imiquimod to trigger or exacerbate psoriasis.
  • Careful monitoring is needed in psoriatic patients undergoing imiquimod therapy.
  • This highlights the complex interplay between immune modulation and autoimmune skin conditions.